[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"6df094c2-9111-440a-b8d9-ef9270259908","acronym":"","url":"https://clinicaltrials.gov/study/NCT03961971","created_at":"2021-07-05T17:22:45.637Z","updated_at":"2025-02-25T15:43:33.280Z","phase":"Phase 1","brief_title":"Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM","source_id_and_acronym":"NCT03961971","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • sabatolimab (MBG453)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/18/2020","start_date":" 02/18/2020","primary_txt":" Primary completion: 11/16/2022","primary_completion_date":" 11/16/2022","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-01-03"},{"id":"54e610ca-41de-4129-a9cc-28b0a7d31044","acronym":"SPARC-1","url":"https://clinicaltrials.gov/study/NCT04028245","created_at":"2021-01-29T07:19:33.502Z","updated_at":"2025-02-25T15:43:37.351Z","phase":"Phase 1","brief_title":"A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT04028245 - SPARC-1","lead_sponsor":"Columbia University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • Ilaris (canakinumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 08/15/2019","start_date":" 08/15/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-09"},{"id":"7c689d51-0e44-4011-9164-a6ec2c89625e","acronym":"COMBI-i","url":"https://clinicaltrials.gov/study/NCT02967692","created_at":"2021-01-17T17:17:14.303Z","updated_at":"2024-07-02T16:34:25.889Z","phase":"Phase 3","brief_title":"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma","source_id_and_acronym":"NCT02967692 - COMBI-i","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • BRAF V600","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 569","initiation":"Initiation: 02/17/2017","start_date":" 02/17/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/26/2024","study_completion_date":" 08/26/2024","last_update_posted":"2024-06-14"},{"id":"1f12d403-2fb1-4336-8060-02027bae83cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04294160","created_at":"2021-01-18T20:50:10.771Z","updated_at":"2024-07-02T16:34:27.442Z","phase":"Phase 1","brief_title":"A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer","source_id_and_acronym":"NCT04294160","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • naporafenib (ERAS-254) • batoprotafib (TNO155) • rineterkib (LTT462)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 10/11/2024","primary_completion_date":" 10/11/2024","study_txt":" Completion: 10/11/2024","study_completion_date":" 10/11/2024","last_update_posted":"2024-06-11"},{"id":"fa46a890-7098-41a4-a73e-faad6ef1e43e","acronym":"KontRASt-01","url":"https://clinicaltrials.gov/study/NCT04699188","created_at":"2021-01-19T20:50:07.332Z","updated_at":"2024-07-02T16:34:58.896Z","phase":"Phase 1/2","brief_title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","source_id_and_acronym":"NCT04699188 - KontRASt-01","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • batoprotafib (TNO155) • opnurasib (JDQ443)"],"overall_status":"Recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 01/08/2027","primary_completion_date":" 01/08/2027","study_txt":" Completion: 01/08/2027","study_completion_date":" 01/08/2027","last_update_posted":"2024-06-04"},{"id":"627558e9-c3d7-4f51-90e5-5a44fbbddb52","acronym":"","url":"https://clinicaltrials.gov/study/NCT01351103","created_at":"2021-01-18T05:31:16.537Z","updated_at":"2024-07-02T16:34:59.934Z","phase":"Phase 1","brief_title":"A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands","source_id_and_acronym":"NCT01351103","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF • RNF43","pipe":" | ","alterations":" BRAF mutation • RNF43 mutation","tags":["BRAF • RNF43"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • WNT974"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 06/14/2021","primary_completion_date":" 06/14/2021","study_txt":" Completion: 06/18/2024","study_completion_date":" 06/18/2024","last_update_posted":"2024-05-30"},{"id":"28905f7c-1ba3-4c54-b0ee-8bfef8ba9fd0","acronym":"CDFF332A12101","url":"https://clinicaltrials.gov/study/NCT04895748","created_at":"2021-05-20T11:54:08.339Z","updated_at":"2024-07-02T16:35:03.755Z","phase":"Phase 1","brief_title":"DFF332 as a Single Agent and in Combination With Everolimus \u0026 Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer \u0026 Other Malignancies","source_id_and_acronym":"NCT04895748 - CDFF332A12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2","pipe":" | ","alterations":" VHL mutation • SDHB mutation","tags":["VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation • SDHB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-14"},{"id":"73bc55f4-9097-42c3-8243-1da98bd3cf4a","acronym":"SPARTO","url":"https://clinicaltrials.gov/study/NCT05210413","created_at":"2022-01-29T18:04:48.446Z","updated_at":"2025-02-25T15:54:20.931Z","phase":"Phase 1/2","brief_title":"Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults","source_id_and_acronym":"NCT05210413 - SPARTO","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" PD-L1 • TMB • MSI","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • spartalizumab (PDR001)"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 05/17/2022","start_date":" 05/17/2022","primary_txt":" Primary completion: 11/17/2026","primary_completion_date":" 11/17/2026","study_txt":" Completion: 11/17/2027","study_completion_date":" 11/17/2027","last_update_posted":"2024-04-10"},{"id":"cee602fb-6d33-45f6-b2f6-248a2d8fdf61","acronym":"PLATforM","url":"https://clinicaltrials.gov/study/NCT03484923","created_at":"2021-01-18T17:10:00.250Z","updated_at":"2024-07-02T16:35:22.981Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT03484923 - PLATforM","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" LAG3","pipe":" | ","alterations":" BRAF wild-type","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • Tabrecta (capmatinib) • spartalizumab (PDR001) • Ilaris (canakinumab) • ieramilimab (LAG525)"],"overall_status":"Completed","enrollment":" Enrollment 196","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2024-01-18"},{"id":"ac5acaad-e81c-452a-8add-e324e99252a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02795429","created_at":"2021-06-15T00:55:17.811Z","updated_at":"2024-07-02T16:35:44.225Z","phase":"Phase 1/2","brief_title":"Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC","source_id_and_acronym":"NCT02795429","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" CD8 expression","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 06/15/2016","start_date":" 06/15/2016","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/24/2021","study_completion_date":" 06/24/2021","last_update_posted":"2023-06-30"},{"id":"8b39fe27-0ffb-430b-b908-c4776bc8d456","acronym":"METIMGAST","url":"https://clinicaltrials.gov/study/NCT05135845","created_at":"2021-11-26T14:53:40.144Z","updated_at":"2024-07-02T16:35:56.487Z","phase":"Phase 2","brief_title":"Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma","source_id_and_acronym":"NCT05135845 - METIMGAST","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" HER-2 • MET","pipe":" | ","alterations":" HER-2 positive • MET amplification","tags":["HER-2 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib) • spartalizumab (PDR001)"],"overall_status":"Suspended","enrollment":" Enrollment 90","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-02-03"},{"id":"b81f3d44-5111-4e3a-98b8-7840570a6a03","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499899","created_at":"2021-01-18T17:13:46.749Z","updated_at":"2024-07-02T16:35:56.792Z","phase":"Phase 2","brief_title":"A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer","source_id_and_acronym":"NCT03499899","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • spartalizumab (PDR001) • ieramilimab (LAG525)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 02/27/2020","primary_completion_date":" 02/27/2020","study_txt":" Completion: 11/24/2021","study_completion_date":" 11/24/2021","last_update_posted":"2023-01-30"},{"id":"ea5d6031-d473-42c0-8a28-91a62279cacc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03609424","created_at":"2021-01-18T17:44:34.659Z","updated_at":"2025-02-25T15:43:08.795Z","phase":"Phase 1/2","brief_title":"PDR001 Plus Imatinib for Metastatic or Unresectable GIST","source_id_and_acronym":"NCT03609424","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1","pipe":" | ","alterations":" KIT mutation • KIT exon 9 mutation • KIT exon 13 mutation","tags":["KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 9 mutation • KIT exon 13 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Stivarga (regorafenib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 11/11/2021","primary_completion_date":" 11/11/2021","study_txt":" Completion: 11/11/2021","study_completion_date":" 11/11/2021","last_update_posted":"2023-01-02"},{"id":"f6309da0-cacf-45b1-9ecd-688a82d8475d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02404441","created_at":"2021-01-18T11:28:49.090Z","updated_at":"2024-07-02T16:36:06.170Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of PDR001 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT02404441","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • BRAF • ALK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK translocation","tags":["EGFR • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 319","initiation":"Initiation: 04/27/2015","start_date":" 04/27/2015","primary_txt":" Primary completion: 07/21/2020","primary_completion_date":" 07/21/2020","study_txt":" Completion: 07/21/2020","study_completion_date":" 07/21/2020","last_update_posted":"2022-08-03"},{"id":"ce9c2f83-6e20-41ea-8a52-3b7f9484085f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03668431","created_at":"2021-01-18T17:59:52.829Z","updated_at":"2025-02-25T15:43:12.003Z","phase":"Phase 2","brief_title":"Dabrafenib + Trametinib + PDR001 In Colorectal Cancer","source_id_and_acronym":"NCT03668431","lead_sponsor":"Massachusetts General Hospital","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • BRAF V600 • KRAS wild-type • NRAS wild-type","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • BRAF V600 • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • spartalizumab (PDR001)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-06-27"},{"id":"4c522063-8eba-4680-acba-ac43c6debdef","acronym":"","url":"https://clinicaltrials.gov/study/NCT02900664","created_at":"2021-01-18T14:14:11.436Z","updated_at":"2024-07-02T16:36:14.500Z","phase":"Phase 1","brief_title":"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","source_id_and_acronym":"NCT02900664","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD8 • FOXP3","pipe":" | ","alterations":" TILs","tags":["CD8 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • spartalizumab (PDR001) • nazartinib (EGF816) • CJM112 • Ilaris (canakinumab)"],"overall_status":"Completed","enrollment":" Enrollment 283","initiation":"Initiation: 08/23/2016","start_date":" 08/23/2016","primary_txt":" Primary completion: 03/17/2021","primary_completion_date":" 03/17/2021","study_txt":" Completion: 03/17/2021","study_completion_date":" 03/17/2021","last_update_posted":"2022-03-29"},{"id":"b9b5dae3-5791-48c7-b400-aad98b6dbf14","acronym":"","url":"https://clinicaltrials.gov/study/NCT02605967","created_at":"2021-01-18T12:39:30.324Z","updated_at":"2024-07-02T16:36:17.276Z","phase":"Phase 2","brief_title":"Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT02605967","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • CD8 • IFNG • IL6 • TNFA • CD4","pipe":" | ","alterations":" CD8 expression","tags":["PD-L1 • CD8 • IFNG • IL6 • TNFA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 04/20/2016","start_date":" 04/20/2016","primary_txt":" Primary completion: 11/05/2019","primary_completion_date":" 11/05/2019","study_txt":" Completion: 02/19/2021","study_completion_date":" 02/19/2021","last_update_posted":"2022-02-10"},{"id":"e1ab9724-6bf9-4432-b02c-3c4942410528","acronym":"","url":"https://clinicaltrials.gov/study/NCT02947165","created_at":"2021-01-18T14:28:07.532Z","updated_at":"2024-07-02T16:36:17.808Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.","source_id_and_acronym":"NCT02947165","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD8","pipe":" | ","alterations":" TILs","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • nisevokitug (NIS793)"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 04/25/2017","start_date":" 04/25/2017","primary_txt":" Primary completion: 06/18/2021","primary_completion_date":" 06/18/2021","study_txt":" Completion: 06/18/2021","study_completion_date":" 06/18/2021","last_update_posted":"2022-01-31"},{"id":"db4851dd-1f9c-4dc1-b478-d957077c8416","acronym":"","url":"https://clinicaltrials.gov/study/NCT03647488","created_at":"2021-01-18T17:54:15.660Z","updated_at":"2024-07-02T16:36:18.117Z","phase":"Phase 2","brief_title":"Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03647488","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Tabrecta (capmatinib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/26/2018","start_date":" 12/26/2018","primary_txt":" Primary completion: 09/07/2020","primary_completion_date":" 09/07/2020","study_txt":" Completion: 09/07/2020","study_completion_date":" 09/07/2020","last_update_posted":"2022-01-24"},{"id":"f890a20d-bc67-4162-a724-78d3550f47b0","acronym":"AdenONCO","url":"https://clinicaltrials.gov/study/NCT02403193","created_at":"2021-01-18T11:28:24.652Z","updated_at":"2025-02-25T15:42:21.293Z","phase":"Phase 1","brief_title":"Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT02403193 - AdenONCO","lead_sponsor":"Palobiofarma SL","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • taminadenant (NIR178)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 11/24/2021","study_completion_date":" 11/24/2021","last_update_posted":"2022-01-12"},{"id":"1570426e-dfab-4603-9706-8a2e817aff52","acronym":"","url":"https://clinicaltrials.gov/study/NCT03081494","created_at":"2021-01-18T15:10:47.018Z","updated_at":"2024-07-02T16:36:37.481Z","phase":"Phase 1","brief_title":"Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03081494","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS • VEGFA","pipe":"","alterations":" ","tags":["KRAS • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 06/09/2017","start_date":" 06/09/2017","primary_txt":" Primary completion: 05/07/2019","primary_completion_date":" 05/07/2019","study_txt":" Completion: 05/07/2019","study_completion_date":" 05/07/2019","last_update_posted":"2020-12-11"},{"id":"6b761ed4-cd67-479d-9291-b441cf39372d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03982134","created_at":"2021-01-18T19:35:17.237Z","updated_at":"2025-02-25T15:43:35.581Z","phase":"Phase 1","brief_title":"PDR001 + Panobinostat for Melanoma and NSCLC","source_id_and_acronym":"NCT03982134","lead_sponsor":"Muhammad Furqan","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK3 • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • ROS1 fusion","tags":["EGFR • BRAF • ALK • ROS1 • NTRK3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • Farydak (panobinostat)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 05/01/2022","study_completion_date":" 05/01/2022","last_update_posted":"2019-10-04"}]